Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01390
|
|||||
Drug Name |
CP-724714
|
|||||
Synonyms |
CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Breast cancer [ICD11: 2C60-2C6Z] | Phase 1 | [1] | |||
Therapeutic Class |
Anticancer Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C27H27N5O3
|
|||||
Canonical SMILES |
CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)C=CCNC(=O)COC)C
|
|||||
InChI |
InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+
|
|||||
InChIKey |
LLVZBTWPGQVVLW-SNAWJCMRSA-N
|
|||||
CAS Number |
CAS 845680-17-3
|
|||||
Pharmaceutical Properties | Molecular Weight | 469.5 | Topological Polar Surface Area | 98.3 | ||
Heavy Atom Count | 35 | Rotatable Bond Count | 9 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
XLogP |
4.3
|
|||||
PubChem CID | ||||||
PubChem SID |
14907431
, 24164339
, 45621889
, 50100096
, 74684963
, 99436923
, 103641275
, 109693627
, 118049527
, 123051111
, 124757046
, 125163850
, 126726428
, 131480713
, 135263665
, 135653490
, 136340153
, 136367341
, 136367983
, 136920311
, 142560911
, 144115847
, 144236584
, 152258589
, 162011933
, 162037476
, 162202660
, 163642442
, 163686131
, 164825263
, 172086266
, 174561044
, 177749068
, 180371631
, 185998810
, 188899554
, 198937309
, 202547998
, 223366212
, 223669186
, 223705210
, 223936181
, 226472380
, 230530185
, 251971144
, 252160232
, 252215195
, 252219937
, 252471201
, 252543303
|
|||||
ChEBI ID |
CHEBI:91331
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
References | ||||||
1 | ClinicalTrials.gov (NCT00102895) A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer | |||||
2 | Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.